RxDoctor Payments Data

David Michelson, MD

Ophthalmology · la Jolla, CANPI 1013063437

Payments from drug & device makers

$2,618in general payments, 2019–2025

Across 130 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bausch & Lomb Americas Inc.$164
  • Oyster Point Pharma, Inc.$136
  • Rxsight Inc$119
  • Amgen$116
  • Novartis$92
  • plus $496 from 12 others

What the payments were for

  • Food & beverage$2,59999%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,618 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$260,643
Medicare patients
397
Services billed
3,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost170$92,272
XiidraLifitegrast28$43,959
RestasisCyclosporine22$30,356
Alphagan PBrimonidine Tartrate34$14,434
VyzultaLatanoprostene Bunod27$11,440
CombiganBrimonidine Tartrate/Timolol23$7,250
RocklatanNetarsudil Mesylat/Latanoprost12$5,261
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$4,932
ZioptanTafluprost/Pf13$4,720
RhopressaNetarsudil Mesylate13$4,033
SimbrinzaBrinzolamide/Brimonidine Tart11$2,970
Brinzolamide13$2,774
Brimonidine Tartrate34$1,228
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$225
Latanoprost16$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$1,496$144,312249 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$164$55,39955 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$19$9,29425 claims
AlconSimbrinza$26$2,97011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →